» Articles » PMID: 11720891

Increased Serum Osteoprotegerin in Disorders Characterized by Persistent Immune Activation or Glucocorticoid Excess--possible Role in Bone Homeostasis

Overview
Specialty Endocrinology
Date 2001 Nov 27
PMID 11720891
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To investigate the possible role of osteoprotegerin (OPG) in bone metabolism in humans by measuring serum levels of OPG in five well-characterized patient populations with known or suspected pathology in bone homeostasis, but with differences in the pathogenesis of these disturbances.

Design: The study comprised 34 patients with Cushing's syndrome (CS), 24 acromegalic patients, 16 patients with growth hormone deficiency (GHD), 29 HIV-infected patients, 25 patients with common variable immunodeficiency (CVI) and 59 age- and sex-matched healthy controls (CTR).

Methods: Serum levels of tumor necrosis factor (TNF)-alpha, OPG, C-terminal telopeptides of Type-I collagen (CTX-I) and osteocalcin were determined in all study subjects as well as cortisol (CS and CTR) and IGF-I (acromegaly, GHD and CTR).

Results: OPG levels were significantly elevated in both CVI (median increase approximately 32%, P < 0.05) and HIV-infected patients with especially high levels in the latter group ( approximately 52%, P < 0.001), significantly correlated with increased TNFalpha levels (r = 0.47, P < 0.02). Also CS patients had elevated serum OPG ( approximately 24%, P < 0.01), significantly correlated with increased serum cortisol (r = 0.35, P < 0.05). In contrast, OPG levels in acromegalic and GHD patients were not different from healthy controls. No relationships were found between OPG levels and CTX-I or osteocalcin.

Conclusions: These findings suggest that enhanced OPG levels may be a compensatory response to enhanced osteoclast activity or negative bone remodeling balance in some conditions, but may also be a parameter of enhanced activity in the OPG system possibly correlated to enhanced activity of other members of the TNF family.

Citing Articles

Sclerostin and OPG/RANK-L system take part in bone remodeling in patients with acromegaly.

Halupczok-Zyla J, Jawiarczyk-Przybylowska A, Bolanowski M Front Endocrinol (Lausanne). 2025; 15:1472680.

PMID: 39741885 PMC: 11685073. DOI: 10.3389/fendo.2024.1472680.


Increased Risk of Hip Fracture in Patients with Acromegaly: A Nationwide Cohort Study in Korea.

Kim J, Hong N, Choi J, Moon J, Kim E, Lee E Endocrinol Metab (Seoul). 2023; 38(6):690-700.

PMID: 37899569 PMC: 10764994. DOI: 10.3803/EnM.2023.1782.


Osteoimmunology: The effect of autoimmunity on fracture healing and skeletal analysis.

Loncar S, Halcrow S, Swales D Forensic Sci Int Synerg. 2023; 6:100326.

PMID: 37091290 PMC: 10120377. DOI: 10.1016/j.fsisyn.2023.100326.


Determinants of skeletal fragility in acromegaly: a systematic review and meta-analysis.

Ribeiro de Moura C, Lopes S, Monteiro A Pituitary. 2022; 25(6):780-794.

PMID: 35867180 DOI: 10.1007/s11102-022-01256-6.


Osteoprotegerin Is Associated With Major Bleeding But Not With Cardiovascular Outcomes in Patients With Acute Coronary Syndromes: Insights From the PLATO (Platelet Inhibition and Patient Outcomes) Trial.

Ueland T, Akerblom A, Ghukasyan T, Michelsen A, Aukrust P, Becker R J Am Heart Assoc. 2018; 7(2).

PMID: 29330256 PMC: 5850148. DOI: 10.1161/JAHA.117.007009.